Edition:
United States

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

32.27USD
21 Jul 2017
Change (% chg)

$0.07 (+0.22%)
Prev Close
$32.20
Open
$32.11
Day's High
$32.28
Day's Low
$32.04
Volume
303,698
Avg. Vol
1,367,718
52-wk High
$36.82
52-wk Low
$25.25

Latest Key Developments (Source: Significant Developments)

Spain's Oryzon sees no impact of Roche decision on finances
Thursday, 20 Jul 2017 04:04am EDT 

July 20 (Reuters) - Spain's Oryzon CEO Carlos Buesa::Says the decision by Roche <<>> to drop cancer drug will not have a short-, medium-term impact on Oryzon finances.Says: "The company's capacity to continue developing its business is stable from the financial point of view." .  Full Article

Oryzon says has no collection rights or obligations on Roche deal
Thursday, 20 Jul 2017 03:51am EDT 

July 20 (Reuters) - ORYZON GENOMICS SA ::SAYS HAS NO COLLECTION RIGHTS DERIVED FROM LICENSE AGREEMENT WITH HOFFMANN-LA ROCHE OR OBLIGATIONS ARISING FROM PAST EVENTS.SAYS CHARGES RECEIVED BY COMPANY THROUGHOUT DURATION OF LICENSE AGREEMENT ARE NON-REFUNDABLE.SAYS AT JUNE 30 NET BOOK VALUE OF INTANGIBLE ASSET IS RECORDED AT 328,700 EUROS AND WILL BE FULLY AMORTIZED AS OF DEC. 31.  Full Article

Oryzon Genomics: Roche to discontinue clinical development of ORY-1001
Thursday, 20 Jul 2017 01:14am EDT 

July 20 (Reuters) - ORYZON GENOMICS SA ::SAYS ROCHE DECIDED TO DISCONTINUE CLINICAL DEVELOPMENT OF ORY-1001.SAYS RIGHTS LICENSED TO ROCHE WITH RESPECT TO ORY-1001 WILL REVERT TO ORYZON WHEN TERMINATION OF LICENSE BECOMES EFFECTIVE.SAYS WAS INFORMED THAT DECISION WAS NOT DATA DRIVEN BUT A CONSEQUENCE OF INTERNAL REPRIORITIZATION OF ROCHE’S PIPELINE.  Full Article

Novartis 'cooperating fully' with DOJ, SEC probe of Alcon's Russia, Asia business
Tuesday, 18 Jul 2017 09:28am EDT 

July 18 (Reuters) - Novartis Ag :Says generic dermatology portfolio was hit more severely by u.s. Price pressure as competitors introduced.Ceo says capital market exit for alcon would hinge on 'a few quarters' of growth.Alcon head says intraocular lens issues have stabilized but situation likely to be bumpy in next quarters, 'not declaring victory'.Sandoz head says reception for biosimilar rituximab has been good two weeks after launch.Alcon head says market share losses stabilizing in contact lenses, now on 'a bit of a winning trend'.Cancer unit head says looking at outcomes-based models for pricing cancer cell therapy ctl019, will disclose at launch of product.Cfo says roche stake continues to be a financial investment with strategic component, seeks to maximize value of holding.Says two-thirds of entresto patients are on u.s. Government insurance program medicare.Sandoz unit head says expects speedy rollout of rituximab biosimilar.Ceo says does not know timing of trump administration action on outcomes-based pricing model, expects proposal 'this summer'.Ceo says valuations for m&a make it difficult to find acquisitions between $2 billion-$5 billion that add value, still focused on bolt-on targets to strengthen oncology or differentiated generics business.Alcon head says received u.s. Doj, sec subpoena focusing on alcon's asia and Russia business, covers period before and after novartis owned the business, says cooperating fully.  Full Article

Genentech reports positive phase 3 results for emicizumab in hemophilia A
Monday, 10 Jul 2017 05:30am EDT 

July 10 (Reuters) - Roche Holding Ag ::Positive phase III results for Genentech's emicizumab in hemophilia A published in the New England Journal Of Medicine.Genentech says haven 1 showed emicizumab reduced bleed rate by 87 percent compared with on-demand bypassing agents.Genentech says all 12 secondary endpoints in haven 1 were positive.Genentech says data from haven 1 and haven 2 have been submitted for approval consideration to U.S. FDA and European Medicines Agency (EMA).  Full Article

Roche Holding AG says added 22Q11.2 deletion testing to menu of harmony prenatal test
Wednesday, 28 Jun 2017 10:30am EDT 

June 28 (Reuters) - Roche Holding Ag :Roche Holding Ag - added 22q11.2 deletion testing to menu of harmony prenatal test.Roche Holding Ag- harmony RUO and CE-IVD kit will be available globally in mid-2017.  Full Article

Epizyme expands clinical collaboration with Genentech
Monday, 26 Jun 2017 06:30am EDT 

June 26 (Reuters) - Epizyme Inc :Epizyme expands clinical collaboration to study tazemetostat and tecentriq® combination in nsclc.Epizyme inc - expanded its clinical collaboration with genentech, a member of roche group.Epizyme inc - under new agreement, tazemetostat administered in combination with atezolizumab will be evaluated in a phase 1b/2 clinical study.Epizyme inc - financial terms are not disclosed and epizyme will retain global development and commercialization rights to tazemetostat..Epizyme inc - genentech will sponsor planned phase 1b/2 clinical trial, which is expected to be initiated by end of 2017.  Full Article

Roche says haemophilia drug emicizumab showed positive results
Monday, 26 Jun 2017 02:03am EDT 

June 26 (Reuters) - Roche Holding Ag :Says emicizumab showed positive results in phase iii studies (haven 1 and haven 2) in haemophilia a with inhibitors ahead of an industry meeting in July.  Full Article

Roche receives FDA approval for fourth-gen HIV combination antigen-antibody assay
Friday, 23 Jun 2017 09:20am EDT 

June 23 (Reuters) - Roche Holding Ag :Roche receives fda approval for fourth-generation hiv combination antigen-antibody assay --allowing detection of infection with high sensitivity and specificity.Roche diagnostics - elecsys hiv combi pt assay has received fda pma approval from u.s. Fda.  Full Article

Roche says Ocrevus reduced measures of MS progression
Friday, 23 Jun 2017 02:39am EDT 

June 23 (Reuters) - Roche Holding Ag :Says new data at ean show roche’s ocrevus (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis.  Full Article

Roche's Tecentriq receives positive opinion from EU medicines agency

ZURICH A European Medicines Agency (EMA) panel said on Friday it has recommended Roche's immunotherapy Tecentriq as a treatment for advanced bladder and lung cancer, setting the stage for European Commission approval this year.